Novo Nordisk CEO Says Company Is Struggling in Brazil
The CEO attributed the company's difficulties in Brazil to the loss of semaglutide exclusivity and said price is central to the market.
Related stories
Andersons to Acquire Harvestone for $915 Million
The Andersons agreed to acquire Harvestone Low Carbon Partners for $915 million. About half of the price is attributed to expected 45Z and 45Q tax credit cash flows; closing is exp
M impact | EQUITY | Nov 04, 2026, 11:08 AM UTC
ATS Corporation targets $65 million-$75 million in annualized cost savings
The company says its fixed-cost transformation program is expected to deliver $65 million-$75 million in annualized cost savings.
M impact | EQUITY | Nov 04, 2026, 11:07 AM UTC
New Pacific Metals' Quarterly Net Loss Widens 90% to USD 1.42 Million
New Pacific Metals reported a net loss of USD 1.42 million for the three months ended September 30, 2026, up 90% year-on-year.
M impact | EQUITY | Nov 04, 2026, 11:07 AM UTC
Vermilion Energy Reports Third-Quarter Loss per Share
M impact | EQUITY | Nov 04, 2026, 11:07 AM UTC
Nifty Smallcap 100 Rises 2%, Midcap 100 Gains 1.5%
Broader Indian equity benchmarks outperformed the Sensex and Nifty on Wednesday, November 4.
M impact | EQUITY | Nov 04, 2026, 11:06 AM UTC
Stella-Jones Announces Third-Quarter Results
Stella-Jones reported financial results for the quarter ended September 30, 2026.
M impact | EQUITY | Nov 04, 2026, 11:06 AM UTC